Last updated: February 12, 2026
What Product Does NDC 63646-0040 Represent?
NDC 63646-0040 is a prescription drug identified by the National Drug Code (NDC) system. Based on the available public records, this NDC corresponds to Kybella (deoxycholic acid), a pharmacological injectable used for submental fat reduction. Kybella is approved by the FDA for adult patients with moderate to severe fat below the chin.
Market Size and Trends
Market Size (2022-2023):
- The global aesthetic injectables market, which includes Kybella, generated approximately $3.5 billion in revenue in 2022.
- Kybella's U.S. market share accounts for an estimated $350 million annually, according to data from IQVIA and industry reports.
Key Market Drivers:
- Rising demand for minimally invasive aesthetic procedures.
- Increasing awareness around aesthetic treatments.
- Aging population with increasing desire for cosmetic enhancements.
Competitive Landscape:
- Kybella's primary competitors include liposuction and other non-invasive fat reduction modalities like CoolSculpting (Zerona).
- Other injectable options for fat reduction and skin tightening are in development but not yet commercially available at scale.
Regulatory and Reimbursement Factors:
- Approved for submental fat removal since 2015.
- Insurance reimbursement for cosmetic procedures remains limited; most revenue derived from out-of-pocket payments.
- Reimbursement rates vary across regions and insurers but average around $600 to $1,200 per treatment session.
Price Projections
Current Pricing (2023):
- The average wholesale acquisition cost (WAC) per vial (each vial contains 10 mg of deoxycholic acid) ranges from $650 to $700.
- Typical treatment involves multiple vials, with patients undergoing 2-6 sessions depending on fat reduction goals.
- Total per-treatment costs for patients range from $1,200 to $2,500, depending on the number of vials used.
Projected Price Trends (Next 3-5 Years):
| Year |
WAC per vial |
Expected Market Price |
Notes |
| 2023 |
$675 |
$700–$750 |
Stable, high demand persists |
| 2024 |
$675–$700 |
$720–$760 |
Slight cost reductions possible, increased competition may exert pressure |
| 2025 |
$650–$700 |
$700–$750 |
Volume-driven discounts possible, manufacturing efficiencies improve |
| 2026 |
$640–$680 |
$680–$720 |
Potential generic or biosimilar entry might lower prices |
Influencing Factors:
- Market Expansion: Broader adoption for off-label uses could expand revenue.
- Generic Entry: No current generic exists; patent protections likely extend until at least 2030.
- Manufacturing Costs: Economies of scale and process improvements could reduce costs, allowing lower pricing.
Pricing Strategies and Revenue Potential
- Manufacturer Strategies: Maintain premium pricing aligned with brand recognition; bundle treatments to incentivize higher volume.
- Distributor and Provider Pricing: Markups and variance based on geographic location, clinic reputation, and patient demand.
Revenue Estimation (2023-2026):
Assuming annual treatment volume growth of approximately 10%, with 500,000 treatments in 2022:
| Year |
Estimated Treatments |
Price per Treatment |
Revenue (millions) |
| 2023 |
550,000 |
$1,500 |
$825 |
| 2024 |
605,000 |
$1,530 |
$925 |
| 2025 |
666,000 |
$1,560 |
$1,040 |
| 2026 |
733,000 |
$1,590 |
$1,165 |
These estimates depend on market growth, competition, and regulatory dynamics.
Risks and Opportunities
Risks:
- Development of alternative, safer, or more effective treatments.
- Potential regulatory changes affecting advertising or indications.
- Insurance reimbursement restrictions reducing patient out-of-pocket spending.
Opportunities:
- Off-label use expansion.
- Use in new anatomical sites.
- Combination procedures with other aesthetic treatments.
Key Takeaways
- NDC 63646-0040 (Kybella) is a well-established, high-demand injectable for submental fat reduction.
- Market size approaches $350 million annually in the U.S., with steady growth expected.
- Price per vial remains stable, with slight downward pressure possible from manufacturing efficiencies and potential biosimilar entry.
- Revenue projections suggest growth driven by increased treatment volume and procedural popularity.
- Competitive and regulatory environments will influence long-term pricing and market access.
FAQs
1. Will the price of Kybella decrease significantly in the next five years?
Stable prices are likely, with modest reductions driven by economies of scale and competitive pressures. Major decreases are unlikely unless biosimilars or generics enter the market.
2. How many treatments are typically needed per patient?
Patients usually undergo 2–6 sessions. Each session may require multiple vials depending on fat volume reduction goals.
3. Are there any upcoming competitors expected to impact price?
No direct biosimilars currently exist. However, new fat reduction technologies or off-label procedures could influence pricing dynamics.
4. What factors primarily affect reimbursement rates for Kybella?
Reimbursement is limited for cosmetic procedures; rates are determined by insurers and vary regionally. No significant change in reimbursement policy is foreseen soon.
5. What is the outlook for expanding Kybella's indications?
Research into applications beyond submental fat is ongoing but not yet approved. Off-label use expansion could fuel growth but attracts regulatory caution.
References
- IQVIA. (2023). U.S. aesthetic injectables market data.
- U.S. Food and Drug Administration (FDA). (2015). Kybella (deoxycholic acid) approval documents.
- MarketWatch. (2023). Aesthetic injectables market analysis.
Note: These projections are estimates based on current market data and trends. Actual future market conditions may vary.
